Newsroom | Top Stories | Abbott U.S.
WEBJun 10, 2024 · Abbott Expands its Pure Bliss™ Line of Infant Formulas to Include European-Made and Organic Products; Offers the First and Only Organic Liquid Formula Available at U.S. Retail Stores
Abbott Laboratories (ABT) Latest Stock News & Headlines
WEBGet the latest Abbott Laboratories (ABT) stock news and headlines to help you in your trading and investing decisions.
Abbott Receives U.S. FDA Clearance for Two New Over-the …
WEBABBOTT PARK, Ill., June 10, 2024 / PRNewswire / -- Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) clearance for two new over-the-counter continuous glucose monitoring (CGM) systems – Lingo™ and Libre Rio™, which are based on Abbott's world-leading FreeStyle Libre® continuous glucose monitoring technology 1, now used b...
Abbott MediaRoom - Press Releases
WEBJul 24, 2024 · Abbott Expands its Pure Bliss™ Line of Infant Formulas to Include European-Made and Organic Products; Offers the First and Only Organic Liquid Formula Available at U.S. Retail Stores. Aug 21, 2024.
Abbott Reports Fourth-Quarter and Full-Year 2023 ... - Abbott …
WEBABBOTT PARK, Ill., Jan. 24, 2024 /PRNewswire/ -- Abbott today announced financial results for the fourth quarter ended Dec. 31, 2023. Fourth-quarter sales increased 1.5 percent on a reported basis, 2.1 percent on an organic basis, and 11.0 percent on an organic basis, excluding COVID-19 testing-related sales 1 .
Abbott’s Q4 Earnings Sustain Momentum Into 2024
WEBJan 24, 2024 · Sales for the fourth quarter of 2023 reached $10.2 billion, an 11.0% organic increase, excluding COVID-19 testing-related revenue, driven by Medical Devices (up 15.4% organic; 17.5% reported) and Nutrition (up 13.9% organic; 12.2% reported).
Abbott Labs Q1 Revenue Jumps On Strong Medical Devices Sales, …
WEBApr 17, 2024 · Wednesday, Abbott Laboratories (NYSE:ABT) reported first-quarter sales of $9.96 billion, up 10.8% on an organic basis for the underlying base business, beating the consensus of $9.88 billion....
Abbott Reports First-Quarter 2024 Results and Raises Midpoint of …
WEBApr 17, 2024 · Abbott narrowed its full-year 2024 EPS guidance range. Abbott projects full-year diluted EPS on a GAAP basis of $3.25 to $3.40 and projects adjusted diluted EPS of $4.55 to $4.70, which...
Abbott Q4 Earnings: Continued Resiliency | Abbott Newsroom
WEBJan 25, 2023 · Abbott issued full-year guidance for 2023 adjusted diluted EPS from continuing operations of $4.30 to $4.50. 3 These are the key fourth-quarter highlights: Sales of FreeStyle Libre systems exceeded $1 billion with U.S. sales growing more than 40%.
Abbott says market overestimating sales hit from new diabetes …
WEBOct 18 (Reuters) - Abbott Laboratories (ABT.N) said the market was overestimating the hit to sales of its glucose monitoring products from growing popularity of new diabetes drugs, adding the...
Skip to content